Skip to main content

Table 3 Body weight and fasting blood glucose in CON, CON +50 or 200 mg/kg/day berberine, diabetic, and diabetic +50 or 200 mg/kg/day berberine rats at 8 weeks after STZ-injection in Experiment II and Experiment III

From: Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular Ca2+ handling in smooth muscle cells

 

Initial

8 Week after STZ-injection

Body weight (g)

Blood glucose (mM)

Body weight (g)

Blood glucose (mM)

Experiment II

 CON (n = 10)

187.0 ± 22.8

4.9 ± 1.8

493.0 ± 55.2

5.2 ± 2.3

 CON +50 mg/kg/day berberine (n = 10)

190.5 ± 18.3

4.3 ± 2.0

511.5 ± 62.1

5.7 ± 2.1

 Diabetic (n = 10)

189.0 ± 17.6

4.6 ± 1.9

253.0 ± 72.7*

19.9 ± 4.9*

 Diabetic +50 mg/kg/day berberine (n = 10)

191.0 ± 18.5

4.9 ± 2.5

261.0 ± 68.7#,*

18.2 ± 5.3*

Experiment III

 CON (n = 10)

195.0 ± 23.1

4.5 ± 1.2

503.0 ± 47.9

5.6 ± 1.2

 CON +200 mg/kg/day berberine (n = 10)

196.5 ± 18.6

3.9 ± 2.5

406.5 ± 57.2*

3.7 ± 1.1*

 Diabetic (n = 10)

200.0 ± 21.7

4.3 ± 1.8

296.0 ± 82.1*

18.8 ± 4.5*

 Diabetic +200 mg/kg/day berberine (n = 10)

192.0 ± 17.8

4.4 ± 1.6

381.0 ± 55.8#

10.2 ± 3.7#,*

  1. CON control rats, CON + berberine control rats administrated with berberine, Diabetic diabetic rats, diabetic + berberine diabetic rats administrated with berberine. * P < 0.05 vs. CON and # P < 0.05 vs. diabetic rats